The early results showed that 15 of 41 evaluable patients had objective responses and 32 had stable disease with the ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

Human history was forever changed with the discovery of antibiotics in 1928. Infectious diseases such as pneumonia, tuberculosis and sepsis were widespread and lethal until antibiotics made them ...